
Ornidazole (2% w/w) + Clobetasol (0.05% w/w) + Ofloxacin (0.75% w/w) + Itraconazole (1% w/w)
Active composition
+3 more active ingredients
Ornidazole disrupts DNA synthesis in protozoan organisms, leading to cell death and resolution of infection.
Clobetasol binds to glucocorticoid receptors, inhibiting the transcription of pro-inflammatory genes and reducing inflammation.
Ofloxacin inhibits DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication and transcription.
Itraconazole inhibits the synthesis of ergosterol, disrupting fungal cell membrane integrity.
Medical applications
Winclob-OC Cream is a topical formulation combining Ofloxacin (0.75% w/w), Ornidazole (2% w/w), Itraconazole (1% w/w), and Clobetasol (0.05% w/w) designed for the effective management of mixed bacterial, protozoal, fungal infections, and inflammatory dermatoses. Ofloxacin, a broad-spectrum fluoroquinolone antibiotic, targets gram-positive and gram-negative bacteria by inhibiting DNA gyrase, thereby preventing bacterial replication. Ornidazole, a nitroimidazole derivative, exhibits potent activity against anaerobic protozoa and bacteria by disrupting DNA synthesis. Itraconazole, a triazole antifungal agent, impedes ergosterol synthesis essential for fungal cell membrane integrity, effectively treating dermatophytic and yeast infections. Clobetasol propionate, a potent corticosteroid, provides anti-inflammatory, antipruritic, and vasoconstrictive effects, reducing erythema, swelling, and itching associated with inflammatory skin conditions. The synergistic combination in Winclob-OC Cream offers comprehensive treatment for complex dermatological infections where mixed microbial flora and inflammation coexist. It is indicated for conditions such as infected eczema, dermatitis, fungal-bacterial co-infections, and other inflammatory dermatoses with secondary microbial involvement. Application should follow medical advice, avoiding prolonged use to minimize potential corticosteroid-related adverse effects such as skin atrophy or systemic absorption. Winclob-OC Cream should not be used in viral infections or hypersensitivity to any component.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Safety information not available for this product. Please consult your doctor or pharmacist.
0 reviews for Winclob-OC Cream

Ofloxacin (0.75% w/w) + Ornidazole (2% w/w) + Itraconazole (1% w/w) + Clobetasol (0.05% w/w)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+3 more active ingredients
Ornidazole disrupts DNA synthesis in protozoan organisms, leading to cell death and resolution of infection.
Clobetasol binds to glucocorticoid receptors, inhibiting the transcription of pro-inflammatory genes and reducing inflammation.
Ofloxacin inhibits DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication and transcription.
Itraconazole inhibits the synthesis of ergosterol, disrupting fungal cell membrane integrity.
Medical applications
Winclob-OC Cream is a topical formulation combining Ofloxacin (0.75% w/w), Ornidazole (2% w/w), Itraconazole (1% w/w), and Clobetasol (0.05% w/w) designed for the effective management of mixed bacterial, protozoal, fungal infections, and inflammatory dermatoses. Ofloxacin, a broad-spectrum fluoroquinolone antibiotic, targets gram-positive and gram-negative bacteria by inhibiting DNA gyrase, thereby preventing bacterial replication. Ornidazole, a nitroimidazole derivative, exhibits potent activity against anaerobic protozoa and bacteria by disrupting DNA synthesis. Itraconazole, a triazole antifungal agent, impedes ergosterol synthesis essential for fungal cell membrane integrity, effectively treating dermatophytic and yeast infections. Clobetasol propionate, a potent corticosteroid, provides anti-inflammatory, antipruritic, and vasoconstrictive effects, reducing erythema, swelling, and itching associated with inflammatory skin conditions. The synergistic combination in Winclob-OC Cream offers comprehensive treatment for complex dermatological infections where mixed microbial flora and inflammation coexist. It is indicated for conditions such as infected eczema, dermatitis, fungal-bacterial co-infections, and other inflammatory dermatoses with secondary microbial involvement. Application should follow medical advice, avoiding prolonged use to minimize potential corticosteroid-related adverse effects such as skin atrophy or systemic absorption. Winclob-OC Cream should not be used in viral infections or hypersensitivity to any component.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Safety information not available for this product. Please consult your doctor or pharmacist.
0 reviews for Winclob-OC Cream















